MFJ Stock Chart & Stats
€0.60
€0.01(0.84%)
At close: 4:00 PM EST
€0.60
€0.01(0.84%)
Day’s Range― - ―
52-Week Range€0.46 - €0.87
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€393.79M
Enterprise Value€624.48
Total Cash (Recent Filing)€35.47M
Total Debt (Recent Filing)€17.61M
Price to Earnings (P/E)86.3
Beta1.13
Next Earnings
Mar 02, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume0
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio-1.95
Price to Book (P/B)7.01
Price to Sales (P/S)4.42
P/FCF Ratio67.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.70Price Target Upside16.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€100.02M
Bulls Say, Bears Say
Bulls Say
Revenue And Market ExpansionStrong product growth alongside a larger U.S. hospital account base indicates expanding clinical adoption and market penetration. Broad geographic growth and increasing sales coverage can support durable revenue compounding as Polynovo converts more hospitals and procedures to NovoSorb.
MTX Commercial AdoptionRapid MTX adoption provides a second growth engine within Polynovo’s platform and broadens its commercial footprint beyond the established product base. Wider account penetration and availability across six markets create potential for sustained product-led growth over the coming quarters.
Improved Profitability And Cash GenerationThe return to positive free cash flow and materially higher adjusted EBITDA strengthens Polynovo’s ability to fund manufacturing capacity, clinical work and commercial expansion internally. This improves financial resilience and reduces dependence on external capital while growth investments continue.
Bears Say
Margin VolatilityAlthough Polynovo remains profitable, lower net margin and substantial gross-margin variation indicate that earnings conversion is not yet consistently established. Volatility in product mix, costs or operating leverage could limit the predictability of profit growth as the business scales.
Uneven Cash-flow ConversionRecent cash generation has improved, but the history of negative operating and free cash flow shows that reported earnings do not always convert efficiently into cash. Continued working-capital and investment requirements could constrain internally funded expansion if conversion remains inconsistent.
Regulatory And Reimbursement Execution RiskReimbursement uncertainty could slow provider adoption of SynPath in outpatient settings even though an HCPCS code exists. Separately, PMA review and inspection timing may delay broader U.S. commercialization, making part of the growth strategy dependent on external regulatory and payment decisions.
Polynovo News
MFJ FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was €0.46 and its highest was €0.86 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is €393.79M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Mar 02, 2027 which is in 152 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Aug 25, 2026. The company reported €0.007 earnings per share for the quarter, beating the consensus estimate of €0.005 by €0.002.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of €0.007 in its last earnings report, beating expectations of €0.005. Following the earnings report the stock price went down -4.918%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in DE:MFJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€0.70 (16.96% Upside)
€0.70 (16.96% Upside)
Blogger Sentiment
Bullish
DE:MFJ Sentiment 95%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
MFJ Company Deck
MFJ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates strong commercial momentum across products (notably MTX), significant sales and adjusted EBITDA growth, positive cash generation and strategic investments (new facility, strengthened leadership, clinical evidence). Several manageable near-term headwinds were disclosed: FX volatility, one-off impacts from an R&D lab fire, lumpy large-burn case volumes affecting H2 U.S. growth, reimbursement turbulence for outpatient launches, and timing risks tied to PMA approval and facility transition. Overall the positives (robust growth rates, record months, strong cash flow, substantial MTX adoption and regulatory progress) materially outweigh the challenges, which are largely operational, timing or one-off in nature.View all DE:MFJ earnings summariesMFJ Stock 12 Month Forecast
Average Price Target
€0.70
▲(16.96% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―